Johnson & Johnson (NYSE:JNJ) Shares Acquired by 3Chopt Investment Partners LLC

3Chopt Investment Partners LLC grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,242 shares of the company's stock after purchasing an additional 1,682 shares during the period. 3Chopt Investment Partners LLC's holdings in Johnson & Johnson were worth $2,493,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Principal Financial Group Inc. raised its stake in shares of Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after buying an additional 329,473 shares in the last quarter. Invst LLC grew its holdings in Johnson & Johnson by 394.0% during the third quarter. Invst LLC now owns 10,290 shares of the company's stock worth $1,668,000 after acquiring an additional 8,207 shares during the period. McIlrath & Eck LLC lifted its holdings in Johnson & Johnson by 10.7% in the third quarter. McIlrath & Eck LLC now owns 2,892 shares of the company's stock valued at $469,000 after acquiring an additional 279 shares during the period. Passumpsic Savings Bank purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth $262,000. Finally, Te Ahumairangi Investment Management Ltd grew its stake in shares of Johnson & Johnson by 10.1% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company's stock worth $8,180,000 after purchasing an additional 4,640 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 0.5 %

Shares of Johnson & Johnson stock traded down $0.71 during trading hours on Tuesday, reaching $153.66. 10,723,823 shares of the company's stock were exchanged, compared to its average volume of 7,973,461. The firm has a market capitalization of $370.29 billion, a price-to-earnings ratio of 23.11, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a fifty day moving average of $159.39 and a 200-day moving average of $155.10.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.38%. Johnson & Johnson's dividend payout ratio is 74.59%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. Bank of America reduced their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research note on Thursday, January 23rd. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $163.00 to $164.00 and gave the company an "equal weight" rating in a report on Wednesday, April 9th. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $171.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.